Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: December 4, 2025
Reporting Period: Event-based report regarding Nasdaq listing compliance status.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Nasdaq Non-Compliance Extension: The Company received notification from Nasdaq on December 4, 2025, granting an additional 180-day compliance period to regain compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- New Deadline: The new compliance deadline is June 1, 2026.
- Reason for Deficiency: The Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days prior to the initial notice in June 2025.
- Listing Status: The stock remains listed on the Nasdaq Capital Market during this extension, subject to meeting all other listing requirements (e.g., market value of publicly held shares). A non-compliance indicator will continue to be broadcast.
Guidance, Outlook, and Risks
- Management Plan: The Company intends to actively monitor its stock price and will consider effecting a reverse stock split if necessary to regain compliance.
- Reverse Split Timing: If a reverse stock split is implemented, it must be completed no later than 10 business days prior to the June 1, 2026 expiration date.
- Delisting Risk: If compliance is not demonstrated by June 1, 2026, the Company faces delisting. The Company may appeal to a Hearings Panel, which historically views a near-term reverse stock split as the only definitive plan to resolve bid price deficiencies.
- Forward-Looking Statements: The filing includes standard cautionary language regarding risks and uncertainties that could cause actual results to differ from expectations, referencing risk factors in recent 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the current closing bid price of INTS stock to assess the likelihood of natural compliance without a reverse split.
- Review the Company's recent 10-Q filings (specifically the November 6, 2025 filing) for cash runway and liquidity status, as this filing does not provide financial data.
- Monitor for a formal shareholder proposal or board announcement regarding a reverse stock split, which must be executed by mid-May 2026 to meet the deadline.
- Check the Nasdaq listing center website for the official non-compliance indicator status.